Acetylon Pharmaceuticals is pursuing development of next-generation, selective histone deacetylase (HDAC) enzyme inhibitors with potential for treatment of hematologic and solid tumor cancers, inflammatory diseases such as rheumatoid arthritis, neurodegenerative diseases such as Parkinson's, genetic diseases incluidng sickle cell disease and thalassemia major, and infectious disease such as malaria. Acetylon's technology is being licensed from Harvard University and the Dana Farber Cancer Center. Acetylon raised $7.25M in a Series A finanicng involving private investors including The Kraft Group in July 2009.
View Top Employees from Acetylon Pharmaceuticals, Inc.Website | http://www.acetylon.com |
Revenue | $1 million |
Funding | $100 million |
Employees | 12 (5 on RocketReach) |
Founded | 2008 |
Address | 70 Fargo St. Ste. 205, Boston, Virginia 22713, US |
Phone | (617) 245-1300 |
Fax | (617) 245-1301 |
Technologies |
JavaScript,
HTML,
Twitter
+52 more
(view full list)
|
Industry | Pharmaceuticals, Biotechnology, Pharmaceutical Manufacturing, Drug Discovery, Healthcare, Science and Engineering, Medical Testing & Clinical Laboratories, Medical Device, Health Care, Drug Manufacturing & Research, Pharmaceutical |
Competitors | Acceleron Pharma, Aileron Therapeutics, Merck, Vividion Therapeutics, Inc. |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 325412 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies |
Looking for a particular Acetylon Pharmaceuticals, Inc. employee's phone or email?
The Acetylon Pharmaceuticals, Inc. annual revenue was $1 million in 2023.
Min Yang is the director of biomarker development of Acetylon Pharmaceuticals, Inc..
5 people are employed at Acetylon Pharmaceuticals, Inc..
Acetylon Pharmaceuticals, Inc. is based in Boston, Virginia.
The NAICS codes for Acetylon Pharmaceuticals, Inc. are [32, 325, 325412, 3254, 32541].
The SIC codes for Acetylon Pharmaceuticals, Inc. are [283, 28].